Literature DB >> 10375693

Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation.

L Belayev1, R Busto, W Zhao, G Fernandez, M D Ginsberg.   

Abstract

The present study was conducted to validate a modified method of temporary focal cerebral ischemia in the mouse; neurobehavioral function and histopathological infarction were quantitated following various periods of middle cerebral artery occlusion (MCAo). Male C57BL/6 mice were anesthetized with 3% halothane in a mixture of 30%O2/70%N2O delivered by face mask and were subjected to 30- to 180-min of temporary middle cerebral artery occlusion (MCAo) by an intraluminal suture coated with poly-l-lysine. Twenty-eight of 40 mice showed an initial high-grade neurological deficit (30-min MCAo, n=7; 60-min, n=8; 120-min, n=8; 180-min, n=5) when examined during MCAo; these were used for subsequent study. One day after MCAo, behavioral function was re-evaluated, and brains were perfusion-fixed and infarct volumes were measured. The initial neurological deficit improved at 24 h in mice with 30- or 60-min of prior MCAo but tended to persist in mice with 120- or 180-min insults. Following each duration of ischemia, mice exhibited ipsilateral infarcts. Small, inconsistent predominantly subcortical infarcts were present after 30-min MCAo, while longer occlusion periods gave rise to consistent foci of subcortical infarction involving striatum, septum, thalamus, and hippocampus, as well as areas of frontoparietal cortical infarction. The major advantages of the improved intraluminal MCAo model reported here, incorporating sutures coated with poly-l-lysine, include: a 100% incidence of infarction of predictable location and size in mice having an initial neurological deficit. Periods of 60- to 180-min MCA occlusion in this model yield sufficiently reproducible sequelae to permit the effects of various therapeutic agents on neurological outcome and size of infarction to be readily studied. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375693     DOI: 10.1016/s0006-8993(99)01528-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  42 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

2.  Sensitive detection of GFP utilizing tyramide signal amplification to overcome gene silencing.

Authors:  Zsuzsanna E Toth; Tal Shahar; Ronen Leker; Ildiko Szalayova; András Bratincsák; Sharon Key; Anna Lonyai; Krisztián Németh; Eva Mezey
Journal:  Exp Cell Res       Date:  2007-03-12       Impact factor: 3.905

3.  Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress.

Authors:  Fang Wu; Andrew D Nicholson; Woldeab B Haile; Enrique Torre; Jie An; Changhua Chen; Andrew K Lee; Duc M Duong; Eric B Dammer; Nicholas T Seyfried; Frank C Tong; John R Votaw; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2013-07-24       Impact factor: 6.200

4.  Resveratrol Preconditioning Induces a Novel Extended Window of Ischemic Tolerance in the Mouse Brain.

Authors:  Kevin B Koronowski; Kunjan R Dave; Isabel Saul; Vladimir Camarena; John W Thompson; Jake T Neumann; Juan I Young; Miguel A Perez-Pinzon
Journal:  Stroke       Date:  2015-07-09       Impact factor: 7.914

5.  Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain.

Authors:  Fang Wu; Jialing Wu; Andrew D Nicholson; Ramiro Echeverry; Woldeab B Haile; Marcela Catano; Jie An; Andrew K Lee; Duc Duong; Eric B Dammer; Nicholas T Seyfried; Frank C Tong; John R Votaw; Robert L Medcalf; Manuel Yepes
Journal:  J Neurosci       Date:  2012-07-18       Impact factor: 6.167

6.  A stable focal cerebral ischemia injury model in adult mice: assessment using 7T MR imaging.

Authors:  F Zhang; R-M Guo; M Yang; X-H Wen; J Shen
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 7.  Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.

Authors:  Andrea Lippoldt; Andreas Reichel; Ursula Moenning
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain.

Authors:  Chen Zhang; Jie An; Dudley K Strickland; Manuel Yepes
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.

Authors:  Fang Wu; Ramiro Echeverry; Jialing Wu; Jie An; Woldeab B Haile; Deborah S Cooper; Marcela Catano; Manuel Yepes
Journal:  Mol Cell Neurosci       Date:  2012-10-09       Impact factor: 4.314

10.  Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/reperfusion in rats.

Authors:  Venkata Prasuja Nakka; Anchal Gusain; Ram Raghubir
Journal:  Neurotox Res       Date:  2010-02       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.